[Diabetes mellitus associated with atypical antipsychotic medications: case report and review of the literature].
Since the introduction of atypical antipsychotic medications, starting with clozapine in 1990, many studies have associated these drugs with the development of diabetes among other metabolic disorders, as well as with the onset of the disease as ketoacidosis. We report the case of a 28-year-old patient with schizophrenia who was admitted with diabetic acidosis 1 month after the beginning of clozapine therapy. No weight gain was reported and the patient maintains satisfactory glycemia levels with no treatment required after discontinuation of the drug. The literature on this subject and cases reported so far are reviewed, including the association of other atypical antipsychotic drugs also involved in endocrine disorders. The objective of this report is to raise the awareness of physicians treating psychiatric patients to the possibility of new-onset diabetes during therapy with atypical antipsychotic drugs and to emphasize the necessity for increased vigilance and close metabolic follow-up of these patients.
Reis
Janice Sepúlveda
JS
Serviço de Endocrinologia e Metabologia, Santa Casa de Belo Horizonte, MG. janicesepulveda@terra.com.br
Alvarenga
Tiago
T
Rosário
Pedro Weslley S do
PW
Menezes
Patrícia A F C
PA
Rocha
Roberta Dos Santos
Rdos S
Purisch
Saulo
S
D014150:Antipsychotic Agents / Q000009:adverse effects*; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male
D014150:Antipsychotic Agents; D003024:Clozapine